Editor's Pick: The week ahead....
(FGN.L) FuturaGene PLC Buy/Sell
Add to portfolio Set Alert Level 2 Desktop Trader
Summary
|
|
|||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||
| Date/Time | Headline | Source |
|---|---|---|
| 16-11-09 | RNS |
|
|
RNS Number : 5499C Futuragene PLC 16 November 2009 Form TR-1 with annex. FSA Version 2.1 updated April 2007 For filings with the FSA include the annex For filings with issuer exclude the annex
TR-1: Notifications of Major Interests in Shares
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:
2. Reason for notification (yes/no)
An acquisition or disposal of voting rights An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached An event changing the breakdown of voting rights
Other (please specify):______________
3. Full name of person(s) subject to notification obligation: 4. Full name of shareholder(s) (if different from 3): 10/11/09 5. Date of transaction (and date on which the threshold is crossed or reached if different): 12/11/09 6. Date on which issuer notified:
crossed or reached: 8: Notified Details A: Voting rights attached to shares
GB0031791782
B: Financial Instruments Resulting situation after the triggering transaction
Type of financial instrument Expiration date Exercise/ conversion No. of voting rights Percentage of voting
Total (A+B)
Number of voting rights Percentage of voting rights
9. Chain of controlled undertakings through which the voting rights and /or
the financial instruments are effectively held, if applicable:
SAS Rue La Bo?e
Cr?t Agricole SA
Calyon SA
Cr?t Agricole Cheuvreux SA
Proxy Voting: 10. Name of proxy holder: 11. Number of voting rights proxy holder will cease to hold: 12. Date on which proxy holder will cease to hold voting rights: 13. Additional information:
15. Contact telephone name: 0207 214 5282 For notes on how to complete form TR-1 please see the FSA website. This information is provided by RNS The company news service from the London Stock Exchange END
HOLKQLBFKFBFFBX More |
||
| 12-10-09 | RNS |
|
|
RNS Number : 6004A Futuragene PLC 12 October 2009 Form TR-1 with annex. FSA Version 2.1 updated April 2007 For filings with the FSA include the annex For filings with issuer exclude the annex
TR-1: Notifications of Major Interests in Shares
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:
2. Reason for notification (yes/no)
An acquisition or disposal of voting rights An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached An event changing the breakdown of voting rights
Other (please specify):______________
3. Full name of person(s) subject to notification obligation: 4. Full name of shareholder(s) (if different from 3): 06/10/09 5. Date of transaction (and date on which the threshold is crossed or reached if different): 08/10/09 6. Date on which issuer notified:
crossed or reached: 8: Notified Details A: Voting rights attached to shares
GB0031791782
B: Financial Instruments Resulting situation after the triggering transaction
Type of financial instrument Expiration date Exercise/ conversion No. of voting rights Percentage of voting
Total (A+B) Number of voting rights Percentage of voting rights
9. Chain of controlled undertakings through which the voting rights and /or
the financial instruments are effectively held, if applicable:
SAS Rue La Botie
Cr?t Agricole SA
Calyon SA
Cr?t Agricole Cheuvreux SA
Proxy Voting: 10. Name of proxy holder: 11. Number of voting rights proxy holder will cease to hold: 12. Date on which proxy holder will cease to hold voting rights: 13. Additional information:
15. Contact telephone name: 0207 214 6037 For notes on how to complete form TR-1 please see the FSA website. This information is provided by RNS The company news service from the London Stock Exchange END
HOLVLLBFKBBEFBQ More |
||
| 29-09-09 | RNS |
|
This news article is displayed preformatted as it may contain results tables
RNS Number : 7934Z
Futuragene PLC
29 September 2009
FUTURAGENE PLC
Interim Results
29 September 2009. FuturaGene PLC, ("FuturaGene" or "the Group", AIM: FGN), a leader in plant genetic research and development for global forestry, biofuel and agricultural markets, announces its unaudited interim results for the six months ended 30 June 2009.
Results highlights
* Secured additional investment of £1.37m from International Institute of BioScience Research and Development (IIBRD), increasing its shareholding in the Group to 9%
* On course to securing material recurring revenues within the next two to three years
* Extension of agreement for development of disease-resistant eucalyptus with China Academy of Forestry
* Signed agreement for development of enhanced poplar with the China Academy of Forestry for domestic market
* Management team strengthened
* Second field trial of the modified eucalyptus with Suzano in Brazil produced strong initial results
* Field trials initiated in corn and alfalfa
* Loss after tax of £832,000 (30 June 2008: loss £876,000)
* Cash at period end of £829,000 (30 June 2008: £1.4 million)
Dr. Stanley Hirsch, Group Chief Executive of FuturaGene commented:
"As the pressure on resources, particularly land and water, and the demand for renewable plant-based energy continue to increase worldwide, we are extremely well positioned to provide sustainable, ecologically sound technologies to enhance plant yields and enable marginal land to be more effectively used.
"We are one of the leaders in developing two major clean technology crops: sustainable, plantation eucalyptus, the key crop for the pulp and paper industry; and poplar which is used for carbon neutral energy combustion and the production of liquid biofuel.
"The first half of the year has seen us sign a number of notable development agreements in strategic crops. The IIBRD investment and the linked conversion of commercialisation options by a major strategic partner, consummate years of development work and place us on the path to achieving material recurring revenues within two to three years."
Enquires:
FuturaGene Plc
Mark Pritchard, Chairman +44 (0) 7802 827 846
Dr. Stanley Hirsch, Group Chief Executive +972 544 56 2724
Evolution Securities
Neil Elliot +44 (0) 20 7071 4300
College Hill +44 (0)20 7457 2020
Adrian Duffield/Rozi Morris
Note to Editors:
FuturaGene PLC www.futuragene.com.
FuturaGene is a leader in plant genetic research and development for the global forestry, biofuel, and agricultural markets. The Group develops sustainable, ecologically sound technology to meet the ever increasing demands for fibre, fuel and food crops in the face of declining and deteriorating land and water resources.
FuturaGene aims to be the leading crop technology company for biomass, second generation biofuel and biopower, through two main technology platforms: Cell Wall Modification, which helps crops grow faster, enhancing yield and processability; and Abiotic Stress Tolerance which enables plants to grow in harsh, dry, salty environments or protects yield when plants are stressed by these factors.
The Group has established broad applications of its technology in key crops including eucalyptus, which is the largest sustainable plantation forest species for the pulp and paper industry; and poplar, which is increasingly used as wood chip for biopower, through direct combustion, the co-firing of coal power stations or for the production of liquid biofuel. FuturaGene's technology is also being used in alfalfa and corn, both of which are aimed at the animal feed and biofuel markets.
The Group's most advanced technologies are for yield improvement in sustainable industrial forestry. The Group has successfully completed field trials in this area and is now in regulatory phases prior to commercial deployment. FuturaGene is one of only a very limited number of biotech companies to have taken a genetic trait from discovery to the pre-launch stage. The ability to take a novel gene this far is almost unique outside of the major agricultural-industry players.
FuturaGene also has strong partnerships with leading international forestry and agriculture companies, such as Suzano, Forage Genetics (Land 'O Lakes), China Academy of Forestry (CAF), AA Alliance and Targeted Growth.
Business Overview
The first half of the year saw FuturaGene make considerable progress in its aim to be a leading source of plant genetic solutions for the global forestry, biofuel and agriculture industries with the Group passing a significant milestone towards the commercialisation of genes in its portfolio.
In May 2009, the IIBRD raised its shareholding in the Group to 9% by investing an additional £1.37 million. IIBRD is a subsidiary of a major forestry group. This investment also exercised pre-existing commercialisation options between the Group and IIBRD for the commercial use of genes developed by FuturaGene's subsidiary CBD Technologies.
The directors expect this to lead to the first commercial deployment of FuturaGene's products for eucalyptus by a significant operator in a major plantation-forestry market and put the Group on course to begin booking recurring revenues within the next two to three years.
Additional milestones achieved in the first half of 2009 included an extension of the Group's agreement with the Research Institute of Tropical Forestry (RITF) of the CAF, for the development of growth-enhanced eucalyptus. RITF is the principal research institute for the eucalyptus industry in southern, sub-tropical China and is a major provider of improved germplasm to this fast-growing industry. The eucalyptus estate in southern China has become plagued by a disease, bacterial Wilt, which is killing large numbers of trees. The Group is developing a genetic approach which it believes will be effective against the disease and it extended the agreement with RITF to include this new approach.
The management team was strengthened by the appointment of Dr. Ziv Shani to the Board and by appointment of Dr. Nissim Chen as Director of Business Development at CBD Technologies.
Financial results
The unaudited financial results for the six months to 30 June 2009 record an operating loss of £832,000 (30 June 2008: loss £876,000). The loss per share was 1.9p (30 June 2008: loss 2p). No dividend is being declared. Cash reserves at 30 June 2009 were £829,000 (30 June 2008: £1.4 million). The current cash burn is at the rate of £160,000 per month. The projected cash burn in the second half is expected to be at a level in line with the first six months of the financial year.
Strategic Crops
Eucalyptus
Eucalyptus is the largest sustainable plantation forest species for the pulp and paper industry and represents a major market opportunity for FuturaGene. A second field trial of the Group's modified eucalyptus is underway with the Suzano forestry company in Brazil. The trial has produced strong initial results, which have verified results from earlier trials. With the acquisition of biosafety data, there has been a positive relaxation in the regulatory regimes surrounding the conduct of the trials, including permission for enhanced duration of trials, which allows better data accumulation. The authorities have now also allowed the planting of eucalyptus in the substantial exclusion zones that previously surrounded the trial sites.
FuturaGene and Suzano continue to collaborate on an extensive R&D programme to introduce new genes and improved gene constructs into additional Suzano clones. This research is reinforcing the Group's position as a leader in commercial eucalyptus transformation.
Poplar
FuturaGene's R&D group has successfully developed new transformation methods for the first clones of commercial poplar, which were imported from the USA. All aspects of the Group's technology, including yield, processability, salt tolerance and drought tolerance, will be introduced into poplar.
In addition to this in-house work, the Group has recently announced a Collaborative Development Agreement with the CAF to develop new and enhanced poplar for the Chinese domestic market.
The Group is in the process of developing additional research and commercial partnerships for poplar in the USA in order to strengthen its global position in the crop, which will soon play an important role in the renewable energy market.
There is a growing demand for wood pellets made from poplar woodchip to co-fire coal-fired power stations in the USA and Europe. As poplar can be grown in renewable, sustainable plantations, it provides a carbon neutral source of combustible material for electricity generation.
Poplar is also indicated by the US Department of Agriculture as a preferred source of raw material for second generation (cellulose-to-ethanol) liquid biofuel production.
Research & Development Activities
The Group's licensees continue to report good progress in the work they are doing with FuturaGene's intellectual property.
Forage Genetics Inc.
Forage Genetics is progressing well with development of alfalfa varieties incorporating the Group's genes to enhance digestibility, processability and to shorten crop rotation times. Initial modified plants were produced and introduced into preliminary field trials in 2009. Alfalfa is the fourth biggest crop in the United States and is principally used for animal feed. Alfalfa will also be tested as a second-generation biofuel crop.
Targeted Growth Inc.
Targeted Growth (TGI) has progressed rapidly with corn transformations using the Group's licensed genes to enhance plant processability, digestibility and other agronomic properties. In May 2009, Targeted Growth initiated preliminary field trials with a number of modified corn lines. The trials are aimed at screening for corn lines showing positive traits to take forward in the development pathway.
The agreement was amended to reflect TGI's intention to focus on the enhancement of corn using the Group's technology, rather than begin trials on soybean. As a result, all rights for the soy technology were returned to the Group.
Oregon State University
In May 2009, FuturaGene entered into an agreement with Dr. Steven H. Strauss, a Distinguished Professor of Forest Biotechnology at Oregon State University (OSU), under which FuturaGene will provide Dr. Strauss's research group with a proprietary eucalyptus clone and a highly efficient eucalyptus transformation protocol developed by the Group. The collaboration will enable rapid and efficient evaluation of genes for flowering control and other biosafety aspects of tree modification.
Intellectual Property
FuturaGene continues to build its intellectual property portfolio both through filings based on in-house discoveries and through licensing relationships with universities and other organisations. The highlight for the first half of 2009 was the granting in Japan of a main cell wall modification patent with broad claims - an unusual step for the Japanese patent office.
Current trading and outlook
The Group has had an active first half with its energies focused on building the business and raising profile in key markets. The business development pipeline for the two strategic crops, eucalyptus and poplar, is very active with the Group looking to expand its eucalyptus business model to additional territories. FuturaGene is also actively developing its presence in the USA poplar market where it is establishing research collaborations and exploring potential commercial opportunities for this crop.
Additionally, the Group is progressing towards executing its first outlicensing agreements for technology from its Abiotic Stress platform. Overall the Board is confident that FuturaGene will continue to build on and develop the momentum it has built over the last nine months.
Income Statement for the six months ended 30 June 2009
Six months ended Six months ended Year ended
30 Jun 2009 30 Jun 2008 31 Dec 2008
Unaudited Unaudited Audited
£'000 £'000 £'000
Revenue 28 150 40
Administrative expenses (861) (1,058) (1,577)
Share of losses of Joint - - (69)
Venture
Operating Loss (833) (908) (1,606)
Finance income 1 32 45
Loss before tax (832) (876) (1,561)
Income Tax - - -
Loss for the period (832) (876) (1,561)
attributable to equity holders
of the company
Loss per ordinary share
Basic and Diluted (1.9p) (2.0p) (3.6p)
Statement of comprehensive income for the six months ended 30th June 2009
Six months ended Six months ended Year ended
30 Jun 2009 30 Jun 2008 31 Dec 2008
£'000 £'000 £'000
Loss for the period (832) (876) (1,561)
Exchange movements (74) 16 32
Total recognised loss for the (906) (860) (1,529)
year
Total comprehensive income (906) (860) (1,529)
attributable to owners of the
parent
Consolidated Balance Sheet at 30 June 2009
30 Jun 2009 30 Jun 2008 31 Dec 2008
Unaudited Unaudited Audited
£'000 £'000 £'000
Assets
Non-current assets
Plant, property & equipment 158 72 172
158 72 172
Current assets
Receivables 49 39 198
Cash and cash equivalents 829 1,436 597
878 1,475 795
Total assets 1,036 1,547 967
Liabilities
Current liabilities
Trade and other payables (548) (859) (1,007)
Net current (liabilities)assets 330 616 (212)
Net (liabilities)assets 488 688 (40)
Equity
Share capital 236 215 215
Share premium account 20,364 18,951 18,951
Capital redemption reserve 2,415 2,415 2,415
Profit and loss account - deficit (22,519) (20,893) (21,687)
Foreign Exchange Reserve (8) - 66
Total equity 488 688 (40)
Consolidated cash flow statement for the six months ended 30 June 2009
Six months ended Six months ended Year ended
30 Jun 2009 30 Jun 2008 31 Dec 2008
£'000 £'000 £'000
Unaudited Unaudited Audited
Cash Flows from operating
activities
Cash flows from operations (1,129) (708) (1,506)
Interest received 1 32 45
Net cash used in operating (1,128) (676) (1,461)
activities
Cash from investing activities
Purchase of property, plant - (15) (89)
and equipment
Proceeds from sale of - - 30
property, plant and equipment
Equity capital raised 1,434
Loans granted to joint - (13) -
ventures
Net cash flows used in 1,434 (28) (59)
investing activities
Net increase(decrease) in cash 306 (704) (1,520)
and cash equivalents
Cash and cash equivalents at 597 2,124 2,124
beginning of the period
Exchange difference (74) 16 (7)
Cash and cash equivalents at 829 1,436 597
end of the period
Reconciliation of net loss to net cash flows from operating activities
Loss before tax (832) (876) (1,561)
Interest received (1) 32) (45)
Depreciation of property, plant and equipment 14 17 27
Profit on sale of property plant and equipment (28)
Impairment of loan to joint venture 13
(Increase)Decrease in trade and other receivables 149 58 (100)
Increase/(Decrease) in trade and other payables (473) 112 191
Equity settled share based payment expense 14 10
Cash used in operating activities (1,129) (708) (1,506)
Notes to the Interim report for the six months ended 30 June 2009
1. ACCOUNTING POLICIES
Basis of preparation
These financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) and IFRIC interpretations endorsed by the European Union (EU) and with those parts of the Companies Act 2006 applicable to companies reporting under IFRS.
A summary of the more important Group accounting policies is given below.
These policies have been consistently applied to all the periods presented, unless otherwise stated.
The company is incorporated and domiciled in the UK.
Unaudited accounts for the six months ended 30 June 2009 show that the group incurred a net loss of £0.8 million during that period and that cash balances at 30 June 2009 were £0.8 million.
As part of their considerations of going concern, the directors have prepared working capital projections for the period to 31 March 2011.
The projections are subject to a number of potentially material variables including the timing and extent of future revenues, the ability to control levels of expenditure and the proceeds from potential future fund raising. In order to execute its plans, the company will require additional funding and is considering its options in this respect with financial advisors.
Based on these discussions, whilst there remains uncertainty over the group's future cash flows, the directors are confident of the company's ability to raise funds and therefore consider it appropriate, to prepare the accounts on a going concern basis.
The financial statements do not include adjustments that would result if the company was unable to continue as a going concern.
The information for the year ended 31 December 2008 has been extracted from the audited accounts for that period which have been delivered to the Registrar of Companies and which contained an unqualified audit report, but which drew attention to material uncertainty regarding the Company's and the Group's ability to continue as going concerns, due to the substantial losses incurred, and the net current liabilities reflected in the audited accounts to 31 December 2008.
The results for the six months to 30 June 2009, which have been neither reviewed nor audited, have been prepared on a basis consistent with the accounting policies disclosed in the company's 2008 accounts and do not constitute statutory accounts within the meaning of Section 40 of the Companies Act 1985.
2. Loss per ordinary share
The calculation of loss per ordinary share is based on:
6 months to 6 months to Year to
30 June 2009 30 June 2009 31 Dec 2008
Loss for the period attributable to (£832,000) (£876,000) (£1,561,000)
equity holders of the company
Weighted average number of ordinary 44,305,644 42,736,798 42,679,103
shares in issue during the period
Basic and diluted loss per share (1.9p) (2.0p) (3.6p)
Since the conversion of potential ordinary shares would decrease the net basic loss per share, they are anti-dilutive. Accordingly, diluted loss per share is the same as basic loss per share.
3. Called up equity share capital
The issued share capital at 31st December 2008 was 43,054,121 Ordinary Shares of £0.005 each. On 5th May 2009, it was announced that IIBRD had acquired 4,045,100 Ordinary Shares at 34p each, thus making the total issued capital 47,099,221 Ordinary Shares as at 30 June 2009.
On 8th July 2009 a further 2,323,018 Ordinary Shares were issued in connection with contingent consideration (see Note 5 below) and also on that date, 800,000 new Ordinary Shares were issued to the company's CEO, Dr Stanley Hirsh, as part of his compensation plan.
4. Contingent Consideration
At 31 December 2008, the Company had an outstanding obligation to issue up to a total of approximately 11.3 million ordinary shares under the terms of acquisition agreements, of which approximately 8.6 million contingent shares related to the acquisition of FuturaGene Inc and approximately 2.7 million contingent shares related to the acquisition of CBD. On 8th July 2009, it was announced that agreement had been reached to issue a total of approximately 2.3 million ordinary shares in full and final settlement of all claims relating to Futuragene Inc.
5. Statement Copies
Copies of the interim statement are available from the Company at its Registered Office at 10, Dominion Street, London EC2M 2EE.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IR EASNPALPNEFE
More |
||
| 09-09-09 | RNS |
|
|
RNS Number : 7280Y Futuragene PLC 09 September 2009
FUTURAGENE PLC FuturaGene to develop enhanced poplar for the Chinese biofuel and biopower markets 9 September 2009. Rehovoth, Israel. FuturaGene PLC, ("FuturaGene" or "the Group", AIM: FGN), a leader in plant genetic research and development for global forestry, biofuel and agricultural markets, has entered into an Agreement with the Chinese Academy of Forestry ("CAF") to develop new enhanced poplar with increased yield, processability and abiotic stress characteristics for the Chinese domestic market. Futuragene will provide proprietary genes and technical assistance to Professor Liwang Qi, Chief Expert on Silva Genetics at CAF in Beijing. The programme aims at improving yield, drought and salt tolerance of short-rotation poplar for the biofuel and biomass markets. Woodchip from poplar produced in sustainable, renewable plantations provides a carbon-neutral fuel source for co-firing coal-burning power stations, significantly reducing environmental damage. Poplar is also being developed for the production of second generation cellulose-to-ethanol biofuel. The rapid growth rate of poplar makes this species an ideal candidate for renewable biomass for energy production reducing the need to use food crops as a raw material for liquid fuel production. In addition to development work, field trials and regulatory authorisation will be carried out by CAF. Both parties will have joint rights for commercialisation of varieties produced under the Agreement in the Chinese domestic market. This Agreement is the second collaboration between FuturaGene and CAF. The first agreement was signed in 2007 and aimed at improving yield, processability and disease resistance of eucalyptus trees. Dr. Stanley Hirsch, Group Chief Executive of FuturaGene commented: "We are delighted to be extending our relationship with CAF, following the productive start to our initial eucalyptus-focused collaboration agreement. This agreement on poplar is strategically important to our global initiatives in the development of this crop for biopower and second generation biofuel production. "Poplar is widely used in China as a structural wood, for fibre and to reverse desertification. There is increasing interest in utilising poplar as a carbon neutral biomass for renewable energy. As China is currently one of the largest users of coal, the introduction of poplar as an energy source for combustion, potentially has a substantial global environmental benefit. "Professor Qi has been a significant contributor to poplar research in China and we are sure that this new partnership will bring mutual benefit to both parties." Professor Liwang Qi added "We are confident that Futuragene's technologies can make a significant contribution to the improvement of poplar varieties in China and are pleased to have this opportunity to work closely with them." Contact:
FuturaGene Plc
Evolution Securities
Adrian Duffield/Rozi Morris Note to Editors: Information on Poplar Poplars are one of the most commonly planted species of tree in China. Poplar wood is used for plywood, veneer and structural timber. As this species is fast growing, it is finding increasing use in reafforestation of deserts. Poplar plantations extended over 4.3 million hectares in 2007 (FAO). According to GMO-Safety (a biosafety research portal run on behalf of the German Federal Ministry of Education and Research), China intends to reforest an area of approximately 17 million hectares by the year 2012. In addition, adoption of woodchip co-firing programs for coal fired power stations in China could significantly add to the demand for poplar wood. About FuturaGene PLC www.futuragene.com. FGN is a leading agricultural biotechnology company focused on research, development and commercialization of technologies that provide solutions for agriculture in a changing planet. FGN's technologies play key roles in substantially improving and protecting yields, enhancing processability and environmental sustainability in the forestry, biofuels, biopower and agricultural sectors. In addition to its in-house discovery programme, FuturaGene licenses intellectual property from leading universities in its strategic fields of interest and develops these technologies in its strategic crops. FGN has established numerous commercial and academic partnerships and out licenses to bring its technologies to market. FGN's most advanced technologies for yield improvement in sustainable industrial forestry have successfully completed field trials and are in regulatory phases prior to commercial deployment. About the Chinese Academy of Forestry The Chinese Academy of Forestry (CAF) was founded in 1958 based on the former Central Research Institute of Forestry established in 1953. Its present president is Chen Tong'ai. The academy now has over 4,400 staff, including researchers, engineers, and technicians, involved in more than 150 disciplines and is authorized advanced academic degrees in a number of fields. Having research offices and satellite institutions in a number of sites around China as well as more than 60,000 hectares of experimental lands, CAF is the mainstream of tree development in China This information is provided by RNS The company news service from the London Stock Exchange END
AGRSSMFIASUSELU More |
||
| Date/Time | Subject | Author | ||
|---|---|---|---|---|
| Mon 09:39 | ||||
|
| ||||
|
| ||||
|
the key seems to be the potential for their technology to migrate from Eucalyptus to corn/cotton ( talking to the Chinese here) where the rotation times mean better cash flow for the company.The financing need also I hear coul find an easy solutio while a big German company is ready to sign an access deal with some cash upfront!
More | View thread (5) | Respond | Login to Vote up | Login to Vote down |
||||
| 13-11-09 | ||||
|
| ||||
|
| ||||
|
Patvan bought in myself a few weeks ago whee they dropped... looks a very interesting company with potenially huge upside... and I am excited!
More | View thread (5) | Respond | Login to Vote up | Login to Vote down |
||||
| 11-11-09 | ||||
|
| ||||
|
| ||||
|
do get excited !
More | View thread (5) | Respond | Login to Vote up | Login to Vote down |
||||
| 11-11-09 |
1
|
|||
|
| ||||
|
| ||||
|
have bought 40k at 52p. Met with Co .Very impressive . Major news ahead .very exciting .Looks like a farm in is possible soon . Fund raising not an issue . IMO I see this north of 80p in next 3 weeks.
More | View thread (1) | Respond | Login to Vote up | Login to Vote down |
||||
They have not been approved or issued by Interactive Investor Trading Limited.
Discussion Board Terms & Conditions FSA Market Abuse Fact Sheet
More...